
Formula 1 (FWON.K) has secured a five-year exclusive streaming deal with Apple for Apple TV, commencing in 2026, valued at approximately $750 million ($150 million annually), a substantial increase over its current agreement. This development coincides with FWON.K shares recently declining to a key support level of $95 after reaching a record high, a point from which the stock has historically rebounded. Institutional interest, evidenced by TD Asset Management's acquisition of over $115 million in FWONK shares, suggests a positive outlook for the stock, driven by the league's continued growth and this lucrative new streaming partnership.
Formula 1 (FWON.K) has secured a significant five-year exclusive streaming deal with Apple for Apple TV, commencing in 2026. This partnership is valued at an estimated $750 million, averaging $150 million annually, representing a substantial 66% increase over the current $90 million per year ESPN agreement. This enhanced revenue stream is expected to significantly bolster the league's financial outlook and global reach. Despite this positive development, FWON.K shares recently experienced a decline, hitting a near 5-month low of $94.30 on October 24, following a record high earlier in October 2025. However, the $95 level has historically acted as a major support zone, from which the stock has previously rebounded to new record highs. This technical pattern suggests a potential inflection point for the stock. Adding to the positive sentiment, an SEC filing revealed that TD Asset Management acquired 150,295 FWON.K shares in Q2 2025, now holding over $115 million worth, indicating strong institutional confidence. The league's overall growth trajectory, combined with the strategic Apple partnership, is anticipated to elevate the sport's profile and financial performance, reinforcing a positive long-term outlook for FWON.K.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Overall Sentiment
strongly positive
Sentiment Score
0.80
Ticker Sentiment